Discounted Cash Flow
Barinthus Biotherapeutics Plc. ADR
—
—
Average annual growth rates
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
| Dividends | — | — | — |
Endpoint CAGR (better for long term trend)
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Projected growth rate
—
—
%
%
Historical inputs (10 fiscal years)
| YEAR | Sales | Net Income | Free Cash Flow | Net Margin | EPS (diluted) |
|---|---|---|---|---|---|
| 2020 | $4.8m | $-17.7m | $-11.3m | -367.3% | $-2.24 |
| 2021 | $268.0k (-94.4%) | $-50.9m (-187.3%) | $-33.7m (-197.9%) | -18979.5% (-5067.7%) | $-1.96 (12.5%) |
| 2022 | $44.7m (16580.2%) | $5.3m (110.5%) | $-20.6m (39.0%) | 11.9% (100.1%) | $0.14 (107.1%) |
| 2023 | $2.8m (-93.6%) | $-73.3m (-1473.0%) | $-56.3m (-173.9%) | -2574.5% (-21643.8%) | $-1.91 (-1464.3%) |
| 2024 | $15.0m (425.4%) | $-61.1m (16.7%) | $-29.8m (47.0%) | -408.0% (84.2%) | $-1.55 (18.8%) |
| 2025 | $1.9m (-87.3%) | $-66.4m (-8.8%) | $-48.0m (-61.0%) | -3485.2% (-754.2%) | $-1.64 (-5.8%) |
Base FCF: — (latest fiscal year)
Discount rate: % —
Terminal growth: —
Projection period: — years
Alt A decline yrs:
Alt B total yrs:
Projected cash flows
| Year | Projected cash flow | Discount Factor | Present Value |
|---|
PV of projected FCF: —
Terminal FCF: —
Terminal value: —
PV of terminal value: —
Enterprise value (DCF): —
Current price: —
—Alternative DCF Models
| Model | Fair Value | Upside | PV(FCFs) | PV(Terminal) | Total Years |
|---|---|---|---|---|---|
| Standard (10yr→TV) | — | — | — | — | 10 + TV |
| Alt A (Gradual Decline) | — | — | — | — | — |
| Alt B (30yr Hard Stop) | — | — | — | N/A | — |
This is a simplified DCF model for illustration. It uses reported free cash flow, a single growth assumption, fixed WACC, and a Gordon Growth terminal value. It is not investment advice.